Chronic inflammatory bowel diseases (IBD), specifically Crohn’s disease and ulcerative colitis, represent a significant medical challenge that extends far beyond physical discomfort. These conditions are characterized by persistent, often debilitating inflammation of the gastrointestinal tract, and they carry a long-term risk of severe complications, most notably the development of bowel cancer. Perhaps most distressing is the demographic they often strike: young people. When genetic predisposition aligns with environmental triggers, these diseases typically manifest between the ages of 15 and 29—a critical developmental window that encompasses the final stages of education and the formative years of early career development. Because of the lifelong implications of these conditions, prompt diagnosis and precise, effective treatment are essential for patient quality of life.
Researchers at Charité – Universitätsmedizin Berlin have recently reached a significant milestone in this field. In a study published in the current issue of the journal Nature Immunology, the team identified a specific therapeutic target that plays a decisive role in fueling ongoing inflammatory processes. This discovery provides a potential breakthrough for patients who have historically struggled to find relief through traditional immunosuppressive therapies.
The Burden of Chronic Inflammation
The onset of Crohn’s disease and ulcerative colitis is often insidious, characterized by a mix of gradual decline and sudden, intense flare-ups. Patients frequently endure severe abdominal cramps, chronic diarrhea, significant weight loss, and profound fatigue. Beyond the physical symptoms, these diseases impose a heavy emotional and psychological burden, particularly on young adults navigating the pressures of their early professional and personal lives.
While the two conditions are often grouped together, their physiological impacts differ. Ulcerative colitis is typically localized, affecting only the inner lining of the large intestine. In contrast, Crohn’s disease can affect the entire thickness of the intestinal wall and may manifest anywhere along the digestive tract, including the small intestine, stomach, and esophagus. In both cases, the persistence of chronic inflammation leads to lasting tissue damage and elevates the risk of malignancy.
Current standards of care primarily aim to suppress the immune system as a whole to reduce inflammation. While these treatments can be effective for many, they are broad-spectrum and come with their own sets of risks and limitations. Furthermore, not every patient responds to these traditional methods. Newer therapeutic strategies have begun to shift toward more targeted approaches, aiming to interrupt inflammatory processes by blocking specific messenger substances—the signaling molecules that drive the immune system into overdrive.
Uncovering the Molecular Drivers of Disease
Despite decades of research, the precise etiology of these systemic diseases remains elusive. It is widely accepted that a complex interplay between genetic susceptibility and environmental influences drives their development. For several years, Prof. Ahmed Hegazy of the Department of Gastroenterology, Infectiology, and Rheumatology at Charité has been investigating the intricate defense mechanisms of the gut’s immune system. Through his research, he and his team have identified a specific, damaging interaction between two immune system messenger substances: Interleukin-22 and oncostatin M.
Interleukin-22 is typically recognized as a beneficial protein that supports the cells lining the gut, helping to maintain the integrity of the protective intestinal barrier. Oncostatin M, conversely, is a signaling molecule that plays a complex role in tissue repair and cell differentiation. The researchers discovered that when these two molecules interact in the context of chronic inflammation, they create a destructive synergy.
"At the clinic, we mainly see young patients who are just beginning their professional lives," says Prof. Hegazy. "So far, we have only been able to slow down the progression of the disease and alleviate symptoms. But not all patients respond well to existing treatments, so new therapeutic approaches are urgently needed."
The research team’s previous work focused on the effects of oncostatin M, which they identified as a major pro-inflammatory messenger. Produced by specific immune cells, this protein acts as a catalyst, activating other inflammatory factors and initiating a dangerous chain reaction. "It was especially interesting for us to see that patients with high levels of oncostatin M do not respond to several common therapies," Prof. Hegazy explains. "This means that oncostatin M levels could help predict treatment failure and may serve as a biomarker for more severe disease. That’s exactly where we focused our efforts: we wanted to understand this signaling pathway better and find ways to block it with targeted treatments."
An Uncontrolled Chain Reaction
The team dedicated five years to uncovering exactly how oncostatin M triggers these inflammatory responses. Using animal models followed by the analysis of human tissue samples, they observed the various stages of chronic intestinal disease. Utilizing state-of-the-art single-cell sequencing, the researchers observed something unexpected: in the inflamed gut, a significantly larger number of cell types possessed binding sites—known as receptors—for oncostatin M compared to healthy tissue.
Simultaneously, the researchers observed that additional immune cells began producing the inflammatory protein, further exacerbating the environment. The role of Interleukin-22 proved particularly surprising. While it generally functions to protect the tissue, in this specific inflammatory context, it actually makes the gut lining more sensitive to oncostatin M by increasing the density of its receptors.
"These two immune messengers work together and amplify the inflammation, drawing more immune cells into the intestine, like a fire that keeps getting more fuel and spreads," says Prof. Hegazy. When the research team specifically blocked these oncostatin M binding sites in their models, they observed a significant reduction in both chronic inflammation and the subsequent development of cancer.
A New Horizon for High-Risk Patients
The clinical implications of these findings are substantial. In tissue samples taken from patients with colorectal cancer caused by chronic intestinal inflammation, the researchers found a high density of receptors for oncostatin M specifically surrounding the tumors. This was not observed in the surrounding healthy tissue, strongly suggesting that this signaling pathway is a key driver in the transition from chronic inflammation to malignant cancer.
However, the researchers are careful to note the inherent complexity of these diseases. Chronic inflammation does not progress to cancer in every patient, and the presentation of IBD is highly variable. "Chronic inflammatory bowel diseases are highly complex and differ from person to person," explains Prof. Britta Siegmund, Director of the Clinic for Gastroenterology, Infectiology, and Rheumatology. "That’s exactly what makes them so difficult to treat and predict. Thanks to the role of oncostatin M and its amplifying interaction with interleukin-22, which we have now identified, we have a clearer understanding of what drives chronic inflammation in some patients. This opens the door to developing and testing a new therapeutic approach."
The team’s experimental findings are already moving toward potential clinical application. By specifically disrupting the harmful interaction between Interleukin-22 and oncostatin M, researchers hope to provide a new, more precise way to manage the disease. "Our results provide a strong scientific basis for developing targeted treatments against this inflammation-promoting mechanism in chronic inflammatory bowel disease—particularly in patients with more severe forms of the illness," Prof. Hegazy notes.
Reflecting the urgency of the research, a clinical trial is already underway to test an antibody designed to block the receptors for oncostatin M. For the many young patients facing the lifelong, unpredictable nature of IBD, this development offers a promising path toward more effective, personalized care that could potentially halt disease progression before permanent damage occurs.
